Cernunnos-XLF Deficiency: A Patient Guide

Cernunnos-XLF deficiency is an ultra-rare genetic disorder that affects the very core of how a child’s body maintains its biological instructions. Because of a pathogenic variant in the NHEJ1 gene, the body produces reduced or no functional XLF protein, a critical member of the mechanism that fixes breaks in DNA ^[1]. This defect impacts two vital processes: the ability to mend accidental damage to DNA and the ability to intentionally rearrange DNA to create a diverse and working immune system ^[2]. Without this repair mechanism, the body’s ability to build T-cells and B-cells is impaired, leading to a state of Severe Combined Immunodeficiency (SCID) or combined immunodeficiency that leaves a child highly vulnerable to infections ^[3].

This condition is clinically defined by a characteristic triad of symptoms that many children have early in life. In addition to facing recurrent and often severe infections, children with Cernunnos-XLF deficiency commonly present with microcephaly (a smaller-than-expected head size) and growth failure, where they struggle to gain weight and height at a typical rate ^[1][3]. Because the DNA-repair defect exists in every cell of the body, it also causes a profound sensitivity to ionizing radiation—such as the radiation found in X-rays or certain types of chemotherapy. While unnecessary elective imaging should be avoided, indicated diagnostic scans for life-threatening issues should not be delayed ^[4].

Living with this diagnosis requires a highly specialized approach to daily care and long-term treatment. To protect the child’s vulnerable cells, medical teams must strictly avoid the use of live-attenuated vaccines and minimize radiation exposure whenever possible ^[5]. While various supportive therapies like antibody infusions and preventative antibiotics are used to manage the immune deficiency, the primary established, potentially curative path for the immune system is a Hematopoietic Stem Cell Transplant (HSCT) ^[6]. Due to the child’s extreme radiosensitivity, this transplant must be carefully managed using individualized reduced-intensity conditioning to suppress the old immune system while trying to avoid fatal toxicity to the rest of the body ^[7].

Even after a successful transplant has restored the immune system, the underlying genetic defect remains in the child’s other tissues, necessitating lifelong monitoring. A transplant does not reverse the microcephaly or growth challenges, and the inherent DNA instability means these children carry an observed and theoretical increased risk for secondary blood disorders and certain types of cancers ^[6][8]. Navigating this journey involves a dedicated multidisciplinary team—from immunologists and transplant specialists to neurologists and nutritionists—all working together to support the child’s unique needs and ensure they are protected and monitored with an individualized surveillance plan throughout their life ^[1].